Home › Research › Treatments
ACE trial design: Equol targeting estrogen receptor-β in vascular and cognitive aging
Sekikawa A, Wharton W, Murray-Krezan C, Wu M, Chang Y, Snitz BE, Coccari M, Yang S et al.. Alzheimer's & dementia (New York, N. Y.), 2025-07-01
Topic: Brain proteins, microglia and lab models
In preclinical studies, it has demonstrated vascular protective and antioxidant effects, with emerging evidence suggesting potential neuroprotective properties. Results A total of 1783 individuals were pre-screened, and 764 underwent in-person eligibility assessment.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Sekikawa, A., Wharton, W., Murray-Krezan, C., Wu, M., Chang, Y., Snitz, B. E., et al. (2025). ACE trial design: Equol targeting estrogen receptor-β in vascular and cognitive aging. Alzheimer's & dementia (New York, N. Y.). https://doi.org/10.1002/trc2.70144
Vancouver
Sekikawa A, Wharton W, Murray-Krezan C, Wu M, Chang Y, Snitz BE, et al. ACE trial design: Equol targeting estrogen receptor-β in vascular and cognitive aging. Alzheimer's & dementia (New York, N. Y.). 2025. doi:10.1002/trc2.70144. PMID: 40838083.
BibTeX
@article{sekikawa2025-40838083,
author = {Sekikawa, A. and Wharton, W. and Murray-Krezan, C. and Wu, M. and Chang, Y. and Snitz, B. E. and Coccari, M. and Yang, S. and others},
title = {{ACE trial design: Equol targeting estrogen receptor-β in vascular and cognitive aging}},
journal = {Alzheimer's \& dementia (New York, N. Y.)},
year = {2025},
doi = {10.1002/trc2.70144},
pmid = {40838083},
url = {https://doi.org/10.1002/trc2.70144}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- In preclinical studies, it has demonstrated vascular protective and antioxidant effects, with emerging evidence suggesting potential neuroprotective properties.
- Results A total of 1783 individuals were pre-screened, and 764 underwent in-person eligibility assessment.
Why it matters
This is a trial design paper, so no results on whether equol affects vascular or cognitive aging are available yet. The neuroprotective suggestion comes only from preclinical studies, not from people.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designrandomized controlled trial
- Participants185
- Evidence strengthHigh
How this study scored 62/100
Published in a leading specialty journal, and it is a randomised controlled trial. Scored zero for effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia (New York, N. Y.)) |
| Journal's citation record | 1 / 4 | Alzheimer s & Dementia Translational Research & Clinical Interventions: journal h-index 84 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomised controlled trial |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 185 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 1 / 2 | Randomised (as stated in the record) |
| Times cited | 2 / 7 | Cited 6 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 3.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 6 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Timothy M. Hughes: h-index 39 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Pittsburgh: institution h-index 1,470 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 7 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40838083) |
| Free to read | 2 / 2 | Free to read |
| Total | 62 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1002/trc2.70144
- PubMed: 40838083
- Original source →
- Free full text: Alzheimer s & Dementia Translational Research & Clinical Interventions →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Treatments
Also tagged “double-blind”
783 studies in the library carry the topic tag “double-blind”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.